IF CLR01 (molecular tweezer, lysine-encapsulating supramolecular ligand; 2.5 mg/kg/day subcutaneous, dose extrapolated from murine efficacy range in established models) is administered chronically (12 weeks) to aged wild-type C57BL/6J mice (both sexes, 24 months), a population that naturally accumulates co-deposited amyloid species across multiple organ systems without transgenic overexpression of any single protein,

THEN a statistically significant, multi-organ reduction in total quantifiable amyloid burden — measured by mass-spectrometry-based quantitative proteomics of guanidine-extracted, amyloid-enriched tissue fractions from heart, brain, and kidney, alongside functional endpoints (echocardiographic left ventricular wall thickness, Morris water maze latency, and glomerular filtration rate) — will be observed compared to age-matched vehicle-treated controls, with effect sizes of ≥25% reduction in amyloid load in at least two of three target organs,

BECAUSE the following causal chain operates simultaneously across multiple amyloid species already deposited in aged tissues:

1. Aged wild-type C57BL/6 mice accumulate naturally occurring transthyretin (ATTR)-like cardiac deposits, low-level Aβ-related cerebrovascular amyloid, and IAPP-associated pancreatic/vascular deposits — substrates that share the defining structural feature of exposed lysine residues critical for amyloid nucleation and fibril stabilization, but which have never been addressed simultaneously as a poly-amyloid repair target in a single non-transgenic model (CLR01 inhibits TTR amyloidosis in vivo by engaging the 8 solvent-exposed lysine residues per TTR monomer, including Lys9, Lys15, Lys35, Lys48, Lys70, Lys76, Lys80, and Lys126)[https://doi.org/10.1007/s13311-013-0256-8].

2. CLR01's process-specific mechanism — threading the ε-ammonium group of labile, solvent-exposed lysine residues into its hydrophobic cavity and forming a salt bridge with its phosphate ions — disrupts the electrostatic and hydrophobic intermolecular contacts required for cross-β sheet elongation across all amyloid species bearing such residues, converting existing toxic oligomers and pre-fibrillar species into non-toxic, amorphous aggregates that are preferentially cleared by cellular proteostasis machinery (CLR01 forces amyloidogenic proteins into off-pathway amorphous aggregates cleared by cellular mechanisms, rather than stable fibrils)[https://doi.org/10.1007/s13311-013-0256-8].

3. Because CLR01 preferentially engages lysine residues in disordered, surface-exposed regions rather than those buried in stable intramolecular salt bridges or hydrophobic cores, it avoids off-target disruption of physiologically folded proteins, maintaining a favorable safety window even during chronic systemic administration required for repair of already-deposited amyloid (the compound does not disrupt the function of stably folded proteins, as their lysine residues are typically inaccessible to the tweezer).

4. Subcu...

SENS category: GlycoSENS

Key references: • doi.org/10.1007/s13311-013-0256-8]. • doi.org/10.1007/s13311-013-0256-8] • doi.org/10.1007/s13311-013-0256-8],